Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel F Tyndale

Showing results (41-50 of 359) with videos related to

Pageof 36
Sort By:
British Journal of Pharmacology|June 6, 2006
Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 proteinAnna M Lee, Sharon Miksys, Rachel F Tyndale
Journal of Psychiatry & Neuroscience : JPN|January 17, 2008
Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time courseJiang Yue, Sharon Miksys, Ewa Hoffmann, et al.
Addiction Biology|June 24, 2020
Acute effects of a very low nicotine content cigarette on laboratory smoking lapse: Impacts of nicotine metabolism and nicotine dependenceHera E Schlagintweit, Rachel F Tyndale, Christian S Hendershot
Neuropharmacology|October 14, 2022
CYP2D in the brain impacts oral hydrocodone analgesia in vivoJanielle Richards, Sharon Miksys, Maria Novalen, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|August 8, 2008
Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descentJill C Mwenifumbo, Edward M Sellers, Rachel F Tyndale
Current Topics in Behavioral Neurosciences|February 7, 2015
Pharmacogenetics of nicotine and associated smoking behaviorsJulie-Anne Tanner, Meghan J Chenoweth, Rachel F Tyndale
Drug Discovery Today|June 24, 2003
Decreasing smoking behaviour and risk through CYP2A6 inhibitionEdward M Sellers, Rachel F Tyndale, Leona C Fernandes
European Journal of Pharmacology|March 17, 2009
Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intakeJiang Yue, Jibran Khokhar, Sharon Miksys, et al.
Addiction (Abingdon, England)|October 3, 2018
Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective studyLion Shahab, Linda Bauld, Ann McNeill, et al.
Pharmacogenomics|April 26, 2002
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependenceLisa A Howard, Edward M Sellers, Rachel F Tyndale
Pageof 36

Showing results (41-50 of 359) with videos related to

Sort By:
Pageof 36
British Journal of Pharmacology|June 6, 2006
Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 proteinAnna M Lee, Sharon Miksys, Rachel F Tyndale
Journal of Psychiatry & Neuroscience : JPN|January 17, 2008
Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time courseJiang Yue, Sharon Miksys, Ewa Hoffmann, et al.
Addiction Biology|June 24, 2020
Acute effects of a very low nicotine content cigarette on laboratory smoking lapse: Impacts of nicotine metabolism and nicotine dependenceHera E Schlagintweit, Rachel F Tyndale, Christian S Hendershot
Neuropharmacology|October 14, 2022
CYP2D in the brain impacts oral hydrocodone analgesia in vivoJanielle Richards, Sharon Miksys, Maria Novalen, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|August 8, 2008
Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descentJill C Mwenifumbo, Edward M Sellers, Rachel F Tyndale
Current Topics in Behavioral Neurosciences|February 7, 2015
Pharmacogenetics of nicotine and associated smoking behaviorsJulie-Anne Tanner, Meghan J Chenoweth, Rachel F Tyndale
Drug Discovery Today|June 24, 2003
Decreasing smoking behaviour and risk through CYP2A6 inhibitionEdward M Sellers, Rachel F Tyndale, Leona C Fernandes
European Journal of Pharmacology|March 17, 2009
Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intakeJiang Yue, Jibran Khokhar, Sharon Miksys, et al.
Addiction (Abingdon, England)|October 3, 2018
Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective studyLion Shahab, Linda Bauld, Ann McNeill, et al.
Pharmacogenomics|April 26, 2002
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependenceLisa A Howard, Edward M Sellers, Rachel F Tyndale
Pageof 36